Mallinckrodt plc (MNK) Shares are Down -8.56%

Mallinckrodt plc (MNK) : During the past 4 weeks, traders have been relatively bearish on Mallinckrodt plc (MNK), hence the stock is down -3.13% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -8.71% relative to the S&P 500. The 4-week change in the price of the stock is -3.65% and the stock has fallen -8.56% in the past 1 week.

The stock has recorded a 20-day Moving Average of 5.74% and the 50-Day Moving Average is 6.95%.The 200 Day SMA reached 5.24%


Mallinckrodt plc (NYSE:MNK): After opening at $69.23, the stock dipped to an intraday low of $68.46 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $70.33 and the buying power remained strong till the end. The stock closed at $69.78 for the day, a gain of 1.15% for the day session. The total traded volume was 1,316,444. The stocks close on the previous trading day was $69.78.

Mallinckrodt plc (MNK) : The highest short term price target forecast on Mallinckrodt plc (MNK) is $115 and the lowest target price is $82. A total of 11 equity analysts are currently covering the company. The average price of all the analysts is $94.55 with a standard deviation of $9.94.

Mallinckrodt public limited company (Mallinckrodt) is a global specialty pharmaceuticals company. The Company develops, manufactures, markets and distributes both branded and generic specialty pharmaceuticals, active pharmaceutical ingredients (API) and diagnostic imaging agents. The Company uses its API products in the manufacture of its generic pharmaceuticals and also sells them to other pharmaceutical companies. The Company operates through two segments: Specialty Pharmaceuticals and Global Medical Imaging. The Companys Specialty Pharmaceuticals segment develops, manufactures and sells, through its Brands business, drugs, including EXALGO (hydromorphone HCl) Extended-Release Tablets and GABLOFEN. The Companys Global Medical Imaging segment develops, manufactures and markets contrast media and delivery systems (CMDS). The Company offers INOMAX Total Care (inhaled nitric oxide), a neonatal critical care product.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.